Cargando…
How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
SIMPLE SUMMARY: Lenalidomide is considered a key drug in the treatment of patients with multiple myeloma (MM), an incurable haematological cancer. In fact, most of the regimens used to treat early stage MM patients contain lenalidomide. This extensive use, however, has now led to treatment resistanc...
Autores principales: | de Arriba de la Fuente, Felipe, Montes Gaisán, Carmen, de la Rubia Comos, Javier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818178/ https://www.ncbi.nlm.nih.gov/pubmed/36612152 http://dx.doi.org/10.3390/cancers15010155 |
Ejemplares similares
-
Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012) -
Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
por: Alegre, Adrian, et al.
Publicado: (2011) -
Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea
por: Kim, Hyo Jung, et al.
Publicado: (2015) -
P24: EXPERT PERSPECTIVES OF UNMET NEED IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE LENALIDOMIDE-SPARING REGIMENS IN EUROPE
por: Mateos, M, et al.
Publicado: (2022) -
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)